胱抑素C在妇科恶性肿瘤患者肾功能损害的评估
Evaluation of Cystatin C in Patients with Gynecological Malignancies with Impaired Renal Function
DOI: 10.12677/ACM.2023.13112588, PDF,   
作者: 樊家岚：江苏大学附属澳洋医院妇科，江苏 张家港
关键词: 胱抑素C；妇科恶性肿瘤；化疗；肾脏损害；Cystatin C； Gynecological Malignancies； Chemotherapy； Renal Impairment
摘要: 目的：探讨胱抑素C在妇科恶性肿瘤患者早期肾功能损害的评估及预后。方法：在江苏大学附属澳洋医院2022年7月~2023年7月期间随机收取妇科恶性肿瘤患者80例、化疗患者80例、健康妇女80例为研究对象，对比三组患者血中Cys-C、SCr、BUN及CCr的水平。结果：恶性肿瘤组的Cys-C和BUN水平均高于对照组(P < 0.05)。化疗组的血清Cys-C和CCr水平均高于对照组(P < 0.05)。恶性肿瘤组的Cys-C水平与已进行≥5次化疗的患者相比差别有统计学意义(P < 0.05)。在恶性肿瘤组和接受≥5次化疗的患者中，血清中的SCr、Cys-C与CCr水平呈负相关。Cys-C在ROC曲线下面积为0.868，P < 0.05，95%置信区间为(0.794, 0.972)。结论：胱抑素C是反映恶性肿瘤患者早期肾功能损害的准确性指标，且可评定肾功能损伤程度而指导用药。
Abstract: Objective: To investigate the assessment and prognosis of cystatin C in early renal impairment in patients with gynecological malignancies. Methods: Eighty patients with gynecological malignancies, 80 patients with chemotherapy and 80 healthy women were randomly enrolled in Aoyang Hospital Affiliated to Jiangsu University during July 2022~July 2023, and the blood levels of Cys-C, SCr, BUN and CCr were compared among the three groups. Results: Cys-C and BUN levels were higher in the malignancy group than the control group levels (P < 0.05). Serum Cys-C and CCr levels in the chem-otherapy group were both higher than the levels in the control group (P < 0.05). The difference in serum Cys-C levels in patients with malignant tumours was statistically significant (P < 0.05) com-pared to patients who received more than five cycles of chemotherapy. In the malignancy group and in patients receiving ≥5 chemotherapy, serum levels of SCr, Cys-C and CCr were negatively correlat-ed. The area under the curve for Cys-C was 0.868, P < 0.05, and the 95% confidence interval was (0.794, 0.972). Conclusion: Cystatin C is an accurate indicator of early renal impairment in patients with malignant tumours and can be used to assess the degree of renal impairment and guide drug use.
文章引用：樊家岚. 胱抑素C在妇科恶性肿瘤患者肾功能损害的评估[J]. 临床医学进展, 2023, 13(11): 18430-18435. https://doi.org/10.12677/ACM.2023.13112588

参考文献

[1] 谢乙宁, 于玲, 谭宏宇. 结直肠恶性肿瘤根治术后急性肾损伤的危险因素[J]. 中华麻醉学杂志, 2021, 41(4): 430-433.
[2] 李娜, 李小平, 王悦, 等. 妇科恶性肿瘤合并肾功能衰竭化疗3例[J]. 实用妇产科杂志, 2017, 33(5): 392-393.
[3] 李娟, 郭志勇. 肿瘤患者肾功能的评估[J]. 上海医学, 2021, 44(9): 641-644.
[4] 董学彩, 杨静, 段树锋. 妇科恶性肿瘤合并癌性腹水患者应用腹腔热灌注化疗的疗效观察[J]. 肿瘤基础与临床, 2017, 30(3): 206-209.
[5] Perazella, M.A. and Rosner, M.H. (2018) Acute Kidney Injury in Patients with Cancer. Oncology (Williston Park), 32, 351-359.
[6] 杨芳, 严哲, 宋娜莎. 恶性肿瘤顺铂化疗对患者p2微球蛋白和胱抑素C及肾功能的影响[J]. 黑龙江医药科, 2023, 45(4): 13-15.
[7] 李海燕. Cys C尧琢1-MG及茁2-MG在慢性阻塞性肺疾病患者的检测价值及与缺氧所致肾损伤的相关性[J]. 分子诊断与治疗杂志, 2020, 12(4): 516-519.
[8] 赵硕, 李望. 前列腺特异性抗原联合胱抑素C和中性粒细胞淋巴细胞比值在前列腺癌中的诊断作用[J]. 中华实验外科杂志, 2020, 37(8): 1437-1441.
[9] Bhatraju, P.K., Chai, X.Y., Stahe, N.A., et al. (2021) Assessment of Kidney Proximal Tubular Secretion in Critical Illness. JCI Insight, 6, Article ID: 145514. [Google Scholar] [CrossRef] [PubMed]
[10] 张毕明, 肖帅, 吴意. 胱抑素C诊断早期急性肾损伤价值的Meta分析[J]. 检验医学与临床, 2018, 15(23): 7-9, 13.
[11] 苏成玉. 氯沙坦治疗慢性肾功能不全合并高血压的短期疗效及对血肌酐、尿素氮、尿酸水平的影响[J]. 临床合理用药杂志, 2019, 12(26): 34-35.
[12] 刘晨露. 甲状旁腺激素、尿素氮与肌酐联合检测在肾功能衰竭早期诊断中应用[J]. 中国社区医师, 2019, 35(25): 116.
[13] 范学明, 王祺, 郑振, 等. 阿托伐他汀治疗老年糖尿病肾病对肾功能及血清胱抑素C、同型半胱胺酸影响研究[J]. 临床军医杂志, 2020, 48(8): 924-925.
[14] 刘景利, 白进川, 杜学成. 糖尿病肾病患者血清淀粉样蛋白A、胱抑素C和25-羟基维生素D水平与肾功能的关系[J]. 江苏医药, 2020, 46(6): 604-607.
[15] 陈静, 王燕, 胡龙妃, 等. 血清胱抑素C、血肌酐及血尿素氮对窒息新生儿肾功能损害的临床意义[J]. 现代生物医学进展, 2019, 19(13): 2547-2550.
[16] 吴义芳, 陈根述, 桂友顺, 等. 血清胱抑素C在高血压早期肾损害诊断中的应用价值[J]. 安微医学, 2022, 38(11): 1470-1472.
[17] 李荣娜, 胡秋霞, 周大敏. 维持性血液透析患者血清同型半胱氨酸、胱抑素C、超敏C反应蛋白水平变化及其与认知功能障碍的相关性分析[J]. 中国医刊, 2021, 56(4): 416-419.
[18] 姚梁, 张培珠, 钟金成. 血液及尿液中Cys C尧KIM-1尧NGAL水平在肝硬化继发急性肾功能损伤患者中的诊断价值[J]. 中国急救复苏与灾害医学杂志, 2021, 16(1): 68-71.
[19] 张蕾. 血清胱抑素C评价肿瘤患者急性肾损伤预后的相关性分析[J]. 医药论坛杂志, 2022, 43(3): 48-51, 55.
[20] 张凤华. 探讨肝病患者胱抑素C测定的临床价值[J]. 中外医疗, 2019, 24(8): 182-184.
[21] 王浩澄, 董娅, 单东凤, 等. 血清胱抑素C、尿酸水平与小细胞肺癌预后的相关性分析[J]. 国际肿瘤学杂志, 2021, 48(1): 24-29.
[22] 王金霞. 血清胱抑素C和β2微球蛋白检测在2型糖尿病肾病早期诊断中的价值[J]. 现代诊断与治疗, 2018, 29(18): 108-110.
[23] 刘道利, 邱芳华, 周伟青, 等. ProGRP、CYFRA21-1和胱抑素C联合检测对不同病理类型肺癌的诊断价值[J]. 检验医学与临床, 2020, 17(1): 9-12.
[24] Ghadrdan, E., Ebrahimpour, S., Sadighi, S., et al. (2020) Evaluation of Urinary Neutrophil Gelati-nase-Associated Lipocalin and Urinary Kidney Injury Molecule-l as Biomarkers of Renal Function in Cancer Patients Treated with Cisplatin. Journal of Oncology Pharmacy Practice, 26, 1643-1649. [Google Scholar] [CrossRef] [PubMed]

为你推荐